Effects of ipragliflozin in patients with type 2 diabetes mellitus, arterial hypertension and left ventricular diastolic dysfunction in a short-term prospective study

S.S. Safronova, I.V. Druk, O.I. Kanunnikova, O.Yu. Korennova, S.P. Podolnaya, T.Yu. Klepatskaya, I.D. Kalinina

1) Omsk State Medical University, Omsk, Russia; 2) Clinical Cardiology Dispensary, Omsk, Russia

Objective: Evaluation of the effect of ipragliflozin on metabolic, hemodynamic parameters, diastolic function (DF) of the left ventricle (LV), adherence to therapy and quality of life of patients with type 2 diabetes mellitus (DM2), arterial hypertension (AH) and left ventricle diastolic dysfunction (LVDD).
Materials and methods: Prospective cohort comparative study was conducted at the Department of Internal Medicine and Family Medicine of Postgraduate Education, Omsk State Medical University. In accordance with the inclusion/exclusion criteria, 2 groups of 30 patients (14/30 men) with DM2, AH and DDLV were formed. Group 1 received ipragliflozin 50 mg per day in monotherapy or in combination with other hypoglycemic drugs. Patients underwent general clinical, laboratory and instrumental studies, physical working capacity test, assessment of quality of life, adherence to therapy and tolerability of the drug.
Results: During the follow-up of 30 patients with DM2, AH and LVDD, who received ipragliflozin, an improvement in metabolic parameters was noted: a decrease in body weight, body mass index (BMI), waist circumference (WC), triglyceride, uric acid, alanine aminotransferase (ALT), glucose, glycated hemoglobin (HbA1c) levels, hemodynamic parameters (a decrease in office BP, daytime BP variability (DBP), nighttime mean BP (NMBP), LV DF, subjective status and quality of life of patients. No serious adverse events or early withdrawal of participants from the study for this reason were registered.
Conclusion: Therapy with ipragliflozin for 12 weeks in a group of patients with DM2, AH and LVDD is accompanied by positive dynamics of metabolic status indicators, BP levels, LVDF with a decrease in the total proportion of people with LVDD, the N-terminal propeptide of natriuretic hormone (NT-proBNP) level in combination with improvement of subjective status and quality of life of patients with good tolerability of therapy and sufficient adherence to treatment.

Keywords

About the Authors

Svetlana S. Safronova, Teaching Assistant, Department of Internal Medicine and Family Medicine of Postgraduate Education, Omsk State Medical University, Omsk, Russia; safronova.sv77@gmail.com, ORCID: https://orcid.org/0000-0001-5852-2782
Inna V. Druk, Dr. Sci. (Med.), Associate Professor, Head of the Department of Internal Medicine and Family Medicine of Postgraduate Education, Omsk State Medical University, Omsk, Russia; drukinna@yandex.ru, ORCID: https://orcid.org/0000-0001-8317-7765 (corresponding author)
Olesya I. Kanunnikova, Associate Professor, Department of Internal Medicine and Family Medicine of Postgraduate Education, Omsk State Medical University, Omsk, Russia; lesia.tch@yandex.ru; ORCID: https://orcid.org/0009-0003-3721-4379
Olga Yu. Korennova, Dr. Sci. (Med.), Professor, Professor at the Department of Internal Medicine and Family Medicine of Postgraduate Education, Omsk State Medical University; Chief Physician, Clinical Cardiology Dispensary, Omsk, Russia; korennova@mail.ru, ORCID: https://orcid.org/0000-0001-8047-5521
Svetlana P. Podolnaya, Cand. Sci. (Med.), Deputy Chief Physician for Outpatient and Polyclinic Work, Clinical Cardiology Dispensary, Omsk, Russia; podolnayasvetlana@mail.ru, ORCID: https://orcid.org/0000-0002-2059-7727
Tatyana Yu. Klepatskaya, Head of Laboratory Department, Clinical Cardiology Dispensary, Omsk, Russia; omskcardio@yandex.ru
Irina D. Kalinina, 2nd year resident in the specialty of endocrinology, Department of Internal Medicine and Family Medicine of Postgraduate Education, Omsk State Medical University Omsk, Russia; irinka_9219@mail.ru

Similar Articles